KPV

5mg Vial

10mg Vial

28 August 2026Updated 29 August 2026

KPV

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for KPV.

Create free account Member login

Full range of benefits for KPV

Anti-inflammatory effects via reduced proinflammatory cytokine release

Downregulates NF-κB signalling in preclinical models

Reduces leukocyte infiltration at sites of inflammation

Promotes mucosal healing in animal models of colitis

Enhances wound closure and tissue repair in skin models

Exhibits direct antimicrobial activity against certain bacteria

Protects epithelial barrier integrity in experimental studies

May reduce oxidative stress and related tissue damage

Modulates macrophage activation toward an anti-inflammatory phenotype

Shows potential to reduce ocular surface inflammation in models

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 14 known interactions

Synergistic(3)Compatible(3)Monitor(4)Avoid(4)

Not recommended for concurrent use

Live attenuated vaccines

Live vaccines should be used with caution around periods of KPV therapy that coincide with other immunomodulators because immune modulation can increase vaccine-related risks or reduce efficacy.

Nonsteroidal anti-inflammatory drugs (NSAIDs)

NSAIDs can impair gastrointestinal mucosal integrity and may counteract KPV's mucosal-protective effects, so evaluate risk–benefit when co-administering for GI conditions.

Protease-based wound debriding agents (e.g., collagenase)

Topical proteolytic debriding agents may degrade KPV at the application site, potentially reducing its local efficacy and therefore require formulation or timing considerations.

Topical antiseptics (e.g., chlorhexidine, alcohol-based cleansers)

Strong antiseptics and solvents can denature peptides on the skin surface and may reduce topical KPV activity, so co-application timing and choice of cleanser should be evaluated.

All interaction categories

Synergistic (3)

Topical corticosteroids (e.g., hydrocortisone): Topical corticosteroids may produce additive anti-inflammatory effects with KPV, enhancing symptom control in inflammatory dermatologic conditions when used together.
Mesalazine (5-aminosalicylic acid): Mesalazine provides complementary mucosal anti-inflammatory activity and may augment KPV's mucosal-healing effects in inflammatory bowel disease.
Probiotics (e.g., Lactobacillus spp.): Probiotic therapy can synergize with KPV by supporting microbiome restoration and barrier function, potentially enhancing reduction of gastrointestinal inflammation.

Compatible (3)

Topical antibiotics (e.g., mupirocin): Topical antibiotics are generally compatible with KPV formulations for local application, with no expected pharmacodynamic antagonism under standard use.
Analgesics (paracetamol/acetaminophen): Paracetamol does not interfere with KPV's known mechanisms of action and is compatible for symptomatic pain control without special adjustments.
Emollients and barrier creams: Emollients and moisturizers are compatible with topical KPV use and may support skin barrier recovery without altering peptide activity.

Monitor (4)

Azathioprine (and other thiopurines): When KPV is combined with systemic thiopurines monitor CBC and liver function tests due to potential additive immunosuppression and hepatotoxicity risk.
Methotrexate: Concomitant use with methotrexate warrants periodic monitoring of full blood count and liver enzymes because of increased immunosuppression and hepatic toxicity potential.
Anti-TNF biologics (e.g., infliximab, adalimumab): Use with anti-TNF agents requires close monitoring for infection signs and baseline/ongoing screening for latent tuberculosis due to increased infection risk.
Systemic corticosteroids: If used with systemic corticosteroids monitor for enhanced immunosuppression and adrenal axis effects and consider adjustments to tapering strategies as clinically indicated.

Avoid (4)

Live attenuated vaccines: Live vaccines should be used with caution around periods of KPV therapy that coincide with other immunomodulators because immune modulation can increase vaccine-related risks or reduce efficacy.
Nonsteroidal anti-inflammatory drugs (NSAIDs): NSAIDs can impair gastrointestinal mucosal integrity and may counteract KPV's mucosal-protective effects, so evaluate risk–benefit when co-administering for GI conditions.
Protease-based wound debriding agents (e.g., collagenase): Topical proteolytic debriding agents may degrade KPV at the application site, potentially reducing its local efficacy and therefore require formulation or timing considerations.
Topical antiseptics (e.g., chlorhexidine, alcohol-based cleansers): Strong antiseptics and solvents can denature peptides on the skin surface and may reduce topical KPV activity, so co-application timing and choice of cleanser should be evaluated.